ESMO 2019 | Phospholipid drug conjugate therapies

Jarrod Longcor

Jarrod Longcor, MA, MBA, Cellectar Biosciences, Madison, WI, outlines the current focus on phospholipid drug conjugate (PDCs), specifically CLR131, and what the future holds for this line of therapy at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics